LT3405495T - Inhibitorių kelių neutralizavimas limfocituose - Google Patents
Inhibitorių kelių neutralizavimas limfocituoseInfo
- Publication number
- LT3405495T LT3405495T LTEP17702315.7T LT17702315T LT3405495T LT 3405495 T LT3405495 T LT 3405495T LT 17702315 T LT17702315 T LT 17702315T LT 3405495 T LT3405495 T LT 3405495T
- Authority
- LT
- Lithuania
- Prior art keywords
- lymphocytes
- neutralization
- inhibitory pathways
- pathways
- inhibitory
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title 1
- 210000004698 lymphocyte Anatomy 0.000 title 1
- 238000006386 neutralization reaction Methods 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281217P | 2016-01-21 | 2016-01-21 | |
| PCT/EP2017/051153 WO2017125532A1 (en) | 2016-01-21 | 2017-01-20 | Neutralization of inhibitory pathways in lymphocytes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3405495T true LT3405495T (lt) | 2021-08-10 |
Family
ID=57944387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP17702315.7T LT3405495T (lt) | 2016-01-21 | 2017-01-20 | Inhibitorių kelių neutralizavimas limfocituose |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10870700B2 (lt) |
| EP (2) | EP3868787A1 (lt) |
| JP (2) | JP7301538B2 (lt) |
| KR (1) | KR20180101549A (lt) |
| CN (2) | CN116327916A (lt) |
| AU (2) | AU2017208554B2 (lt) |
| CA (1) | CA3012055A1 (lt) |
| CY (1) | CY1124212T1 (lt) |
| DK (1) | DK3405495T3 (lt) |
| ES (1) | ES2871112T3 (lt) |
| HR (1) | HRP20210778T1 (lt) |
| HU (1) | HUE054356T2 (lt) |
| IL (1) | IL260464B (lt) |
| LT (1) | LT3405495T (lt) |
| PL (1) | PL3405495T3 (lt) |
| PT (1) | PT3405495T (lt) |
| RS (1) | RS61901B1 (lt) |
| RU (1) | RU2769569C2 (lt) |
| SG (2) | SG10202000645SA (lt) |
| SI (1) | SI3405495T1 (lt) |
| WO (1) | WO2017125532A1 (lt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012009755A (es) | 2010-02-26 | 2012-09-12 | Novo Nordisk As | Composiciones que contienen anticuerpo estable. |
| BR112013032217B1 (pt) | 2011-06-17 | 2021-01-19 | Novo Nordisk A/S | uso de um anticorpo anti-nkg2a |
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| SG10202007781TA (en) | 2014-09-16 | 2020-09-29 | Innate Pharma | Treatment Regimens Using Anti-NKG2A Antibodies |
| PL3193931T3 (pl) | 2014-09-16 | 2021-03-08 | Innate Pharma | Neutralizacja szlaków inhibitorowych w limfocytach |
| EP3209687A1 (en) | 2014-10-23 | 2017-08-30 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| CN107850596B (zh) | 2015-07-24 | 2020-12-04 | 先天制药公司 | 用于检测组织浸润nk细胞的方法 |
| US11795222B2 (en) | 2018-03-13 | 2023-10-24 | Innate Pharma | Treatment of head and neck cancer |
| US20210024633A1 (en) | 2018-03-28 | 2021-01-28 | Ensemble Group Holdings | Methods of treating cancer in subjects having dysregulated lymphatic systems |
| AU2019270277A1 (en) * | 2018-05-15 | 2021-01-07 | Innate Pharma | Treatment of cancer |
| PE20211284A1 (es) * | 2018-11-16 | 2021-07-19 | Bristol Myers Squibb Co | Anticuerpos anti-nkg2a y usos de los mismos |
| JP2022553927A (ja) * | 2019-10-14 | 2022-12-27 | イナート・ファルマ・ソシエテ・アノニム | Ｉｌｔ－２阻害剤での癌の処置 |
| US12071479B2 (en) * | 2020-08-12 | 2024-08-27 | Biond Biologics Ltd. | Antibodies against ILT2 and use thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| GB9725764D0 (en) | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
| BR0311471A (pt) | 2002-05-30 | 2007-04-27 | Macrogenics Inc | anticorpo anti-cd16a, e, métodos de redução de uma resposta imune deletéria em um mamìfero e de tratamento de uma resposta imune deletéria em um mamìfero |
| EP1831258B2 (en) | 2004-12-28 | 2023-06-07 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
| NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| SI1907424T1 (sl) | 2005-07-01 | 2015-12-31 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1) |
| EP2038306B1 (en) | 2006-06-30 | 2014-12-03 | Novo Nordisk A/S | Anti-nkg2a antibodies and uses thereof |
| ES2437327T3 (es) | 2007-06-18 | 2014-01-10 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor PD-1 humano de muerte programada |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| JP5774312B2 (ja) | 2008-01-24 | 2015-09-09 | ノボ・ノルデイスク・エー／エス | ヒト化抗ヒトｎｋｇ２ａモノクローナル抗体 |
| JP2011512332A (ja) | 2008-02-11 | 2011-04-21 | キュアー テック リミテッド | 腫瘍治療のためのモノクローナル抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| CA2992770A1 (en) | 2009-11-24 | 2011-06-03 | Medimmune Limited | Targeted binding agents against b7-h1 |
| MX2012009755A (es) | 2010-02-26 | 2012-09-12 | Novo Nordisk As | Composiciones que contienen anticuerpo estable. |
| RS57324B1 (sr) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antitela i drugi molekuli koji vezuju b7-h1 i pd-1 |
| BR112013032217B1 (pt) | 2011-06-17 | 2021-01-19 | Novo Nordisk A/S | uso de um anticorpo anti-nkg2a |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| ES2746805T3 (es) | 2013-12-12 | 2020-03-06 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo |
| CA2959318A1 (en) | 2014-08-28 | 2016-03-03 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations |
| PL3193931T3 (pl) | 2014-09-16 | 2021-03-08 | Innate Pharma | Neutralizacja szlaków inhibitorowych w limfocytach |
| SG10202007781TA (en) | 2014-09-16 | 2020-09-29 | Innate Pharma | Treatment Regimens Using Anti-NKG2A Antibodies |
| EP3209687A1 (en) | 2014-10-23 | 2017-08-30 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
-
2017
- 2017-01-20 EP EP21158066.7A patent/EP3868787A1/en active Pending
- 2017-01-20 DK DK17702315.7T patent/DK3405495T3/da active
- 2017-01-20 CA CA3012055A patent/CA3012055A1/en active Pending
- 2017-01-20 EP EP17702315.7A patent/EP3405495B1/en active Active
- 2017-01-20 RS RS20210534A patent/RS61901B1/sr unknown
- 2017-01-20 US US16/071,499 patent/US10870700B2/en active Active
- 2017-01-20 RU RU2018125490A patent/RU2769569C2/ru active
- 2017-01-20 PL PL17702315T patent/PL3405495T3/pl unknown
- 2017-01-20 PT PT177023157T patent/PT3405495T/pt unknown
- 2017-01-20 JP JP2018537834A patent/JP7301538B2/ja active Active
- 2017-01-20 AU AU2017208554A patent/AU2017208554B2/en active Active
- 2017-01-20 SG SG10202000645SA patent/SG10202000645SA/en unknown
- 2017-01-20 SI SI201730735T patent/SI3405495T1/sl unknown
- 2017-01-20 HU HUE17702315A patent/HUE054356T2/hu unknown
- 2017-01-20 CN CN202210915090.1A patent/CN116327916A/zh active Pending
- 2017-01-20 WO PCT/EP2017/051153 patent/WO2017125532A1/en active Application Filing
- 2017-01-20 SG SG11201805831RA patent/SG11201805831RA/en unknown
- 2017-01-20 LT LTEP17702315.7T patent/LT3405495T/lt unknown
- 2017-01-20 CN CN201780007833.2A patent/CN108884163B/zh active Active
- 2017-01-20 KR KR1020187023541A patent/KR20180101549A/ko active Search and Examination
- 2017-01-20 ES ES17702315T patent/ES2871112T3/es active Active
-
2018
- 2018-07-08 IL IL260464A patent/IL260464B/en unknown
-
2020
- 2020-12-21 US US17/128,241 patent/US20210122821A1/en not_active Abandoned
-
2021
- 2021-05-11 CY CY20211100401T patent/CY1124212T1/el unknown
- 2021-05-14 HR HRP20210778TT patent/HRP20210778T1/hr unknown
-
2023
- 2023-06-09 US US18/331,966 patent/US20230303691A1/en active Pending
- 2023-06-21 JP JP2023101829A patent/JP7531667B2/ja active Active
-
2024
- 2024-04-18 AU AU2024202552A patent/AU2024202552A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201702642B (en) | Neutralization of inhibitory pathways in lymphocytes | |
| IL260464B (en) | Neutralization of inhibition pathways in lymphocytes | |
| IL256993B (en) | bracket screws | |
| IL288147A (en) | ras inhibitory peptides and their uses | |
| EP3316884A4 (en) | THERAPEUTIC INHIBITING COMPOUNDS | |
| HK1252645A1 (zh) | 按摩機 | |
| IL260193A (en) | Tlr inhibitory oligonucleotides and their use | |
| ZA201800413B (en) | Dry suit | |
| PL3285606T3 (pl) | Ochrona ciała | |
| EP3414686A4 (en) | AUTOMATIC DETECTION OF MALFUNCTION IN SURGICAL TOOLS | |
| SG11201701717UA (en) | Antiviral agents and uses thereof | |
| SG10201606767SA (en) | Direct resistivity determination | |
| DK3274600T3 (da) | Gevindisætningsfejlhæmmende hanfastgørelseselement | |
| SG11201710519PA (en) | Evaluation of inhibitory circuit and use thereof | |
| EP3387530C0 (en) | SECURE COMPUTER | |
| HK1209364A1 (en) | Use of actinomyces naeslundii in the treatment or prevention of rheumatoid arthritis or related diseases | |
| IL247732A0 (en) | Perinase inhibitory peptides and their use in the treatment of clinical pathologies | |
| AU5563P (en) | Viclow Acmena smithii | |
| GB201607978D0 (en) | Inhibitory compounds | |
| HK1209356A1 (en) | Use of sutterella wadsworthensis in the treatment or prevention of rheumatoid arthritis or related diseases | |
| GB201521152D0 (en) | Dictionary/thesaurus | |
| GB201517185D0 (en) | Towel | |
| GB201508876D0 (en) | Sanitary protection | |
| GB201509863D0 (en) | Shower arrangement | |
| GB201508203D0 (en) | Water Ect |